Pfizer’s Xeljanz arthritis drug approved
Pfizer Inc. has been cleared by the Food and Drug Administration to market Xeljanz, a medication for rheumatoid arthritis. The company said Wednesday that Xeljanz (tofacitinib citrate) represents the first new oral disease-modifying antirheumatic drug for rheumatoid arthritis (RA) in over 10 years.